A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
BeOne Medicines
Novartis
Kivu Bioscience Inc.
AstraZeneca
BeOne Medicines
National Cancer Institute (NCI)
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Novartis
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Conjupro Biotherapeutics, Inc.
GlaxoSmithKline
SystImmune Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Orano Med LLC
Stanford University
Tomsk National Research Medical Center of the Russian Academy of Sciences
ViroMissile, Inc.
Replimune, Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
SystImmune Inc.
SN BioScience
Eli Lilly and Company
Oscotec Inc.
Eli Lilly and Company
Sichuan Baili Pharmaceutical Co., Ltd.
Jacobio Pharmaceuticals Co., Ltd.
NextCure, Inc.
Shanghai Juncell Therapeutics
AbbVie
The First Affiliated Hospital of Xinxiang Medical College
Second Affiliated Hospital, School of Medicine, Zhejiang University
Abramson Cancer Center at Penn Medicine
Daiichi Sankyo
AstraZeneca
SystImmune Inc.
Actym Therapeutics, Inc.
Taiho Oncology, Inc.
Olema Pharmaceuticals, Inc.